Skip to main content
S&P 5007,568.92+0.36%DOW51,786.72-0.38%NASDAQ25,372.01+0.83%BTC$77,787.00+1.42%ETH$2,289.17+1.82%GOLD$3,931.60-0.96%OIL$96.58+0.12%
Smart Investors Daily
SID Premium
SV

NASDAQ · SVRA

Savara Inc.

Healthcare · Biotechnology

$4.73

Up+$0.02 (+0.42%)

Updated Nov 3, 2026, 9:01 PM

SID Score

3.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.41B
P/E ratio
-13.6
Dividend yield
0.00%
52-week range
$4.13 – $6.48
Volume
1.78M
Avg. volume
1.96M

Price performance · SVRA

SVRA price history

1M range · 0 trading sessions · Daily adjusted prices

SVRA does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest SVRA news

The latest Smart Investors Daily articles mentioning SVRA.

Stock researchCompany · Overview

SVRA research

Overview

Company profile and research snapshot.

Company profile

Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$9.00
Implied upside
—
Analysts
—
SVRA recent ratings
DateFirmRatingTarget
Oct 7, 2026JP MorganOverweight—
Dec 23, 2025HC Wainwright & Co.Buy—
Dec 18, 2025Wells FargoOverweight—
Nov 14, 2025OppenheimerOutperform—
Nov 13, 2025CitizensMarket Outperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 21, 2026

Savara Presented New Data Showing Molgramostim Inhalation Solution (Molgramostim) Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patients with Mild Diffusion Impairment

YARDLEY, Pa., October 21, 2026--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the CHEST 2026 Annual Meeting in Phoenix, Arizona. The poster reports a post-hoc analysis of the IMPALA clinical trial evaluating the effects of molgramostim in aPAP patients with mildly decreased or normal diffusion capacity, defined as a baseline percent predicted hemoglobin-adjusted diffusing capacity of the lungs for

Yahoo · Oct 13, 2026

Will Long‑Term Molgramostim Data at CHEST 2026 Change Savara's (SVRA) Autoimmune PAP Narrative?

Savara Inc. announced that CHEST 2026 accepted an encore oral presentation on Phase 3 IMPALA-2 data and a poster on Phase 2/3 IMPALA molgramostim data in autoimmune pulmonary alveolar proteinosis, both to be presented in Phoenix, Arizona, on October 18–21, 2026. The focus on long-term efficacy and safety, plus outcomes in patients with mild diffusion impairment, highlights how comprehensively molgramostim is being evaluated for autoimmune pulmonary alveolar proteinosis. With this fresh focus...

Yahoo · Oct 12, 2026

Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026

YARDLEY, Pa., October 12, 2026--Savara Inc. (Nasdaq: SVRA), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of an encore oral presentation on data from the Phase 3 IMPALA-2 clinical trial and a poster presentation on data from the Phase 2/3 IMPALA clinical trial at CHEST 2026 in Phoenix, Arizona, October 18–21.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By